EUVIMEDEUVIMED entdecken
Crossref

Erythropoietic protoporphyria and afamelanotide: a patient’s perspective

Marese O'Reilly, Vicky A McGuire, Robert S Dawe

Clinical and Experimental Dermatology · 2024

DOI: 10.1093/ced/llad346 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Marese O'Reilly und 2 weiteren Autor:innen. Beteiligte Einrichtung: Photobiology Unit. Hauptthemen laut MEDLINE: Protoporphyria, Erythropoietic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 5 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The patient explores the profound impact of erythropoietic protoporphyria (EPP) on her life to date. The clinician’s comment reviews the symptoms and diagnostic criteria for EPP, as well as the novel treatment afamelanotide for EPP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protoporphyria, ErythropoieticHumansalpha-MSH

Substanzen

afamelanotidealpha-MSH

Autor:innen und Institutionen

  • Photobiology Unit.
  • Scottish Cutaneous Porphyria Service, Ninewells Hospital, Dundee, UK.

Zitieren

APA

O'Reilly, M., McGuire, V. A., & Dawe, R. S. (2024). Erythropoietic protoporphyria and afamelanotide: a patient’s perspective. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad346

Vancouver

O'Reilly M, McGuire VA, Dawe RS. Erythropoietic protoporphyria and afamelanotide: a patient’s perspective. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llad346

BibTeX
@article{OReilly2024,
  author = {O'Reilly, Marese and McGuire, Vicky A and Dawe, Robert S},
  title = {Erythropoietic protoporphyria and afamelanotide: a patient’s perspective},
  journal = {Clinical and Experimental Dermatology},
  year = {2024},
  doi = {10.1093/ced/llad346}
}
Kostenlos starten →